Krystal Biotech (NASDAQ:KRYS) Given New $412.00 Price Target at Citigroup

Key Points

• Citigroup lowered Krystal Biotech’s price target slightly from $416 to $412 while maintaining a “Buy” rating, implying roughly 36% upside from the stock’s $302.40 trading price.
• Analyst sentiment remains broadly positive: MarketBeat reports a “Moderate Buy” consensus and an average target price of $375, despite mixed revisions from other brokerages.
• Krystal exceeded third-quarter expectations with $2.05 in EPS and $127.34 million in revenue, but earnings declined year over year and several pipeline milestones have been pushed into 2027, creating valuation and execution concerns.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) had its target price dropped by stock analysts at Citigroup from $416.00 to $412.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm presently has a "buy" rating on the stock. Citigroup's target price would indicate a potential upside of 36.24% from the company's current price.

Several other brokerages have also recently weighed in on KRYS. William Blair upgraded Krystal Biotech to a "strong-buy" rating in a research note on Wednesday, September 23rd. TD Cowen reduced their target price on shares of Krystal Biotech from $403.00 to $380.00 and set a "buy" rating for the company in a research note on Tuesday. Bank of America upped their target price on shares of Krystal Biotech from $392.00 to $400.00 and gave the stock a "buy" rating in a research note on Monday, September 21st. The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a report on Thursday, September 24th. They issued a "buy" rating and a $441.00 target price for the company. Finally, Zacks Research lowered shares of Krystal Biotech from a "hold" rating to a "strong sell" rating in a research report on Friday, October 23rd. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $375.00.

Krystal Biotech Trading Up 2.2%

NASDAQ KRYS traded up $6.50 during trading hours on Tuesday, hitting $302.40. The company's stock had a trading volume of 245,783 shares, compared to its average volume of 328,258. Krystal Biotech has a 52 week low of $192.52 and a 52 week high of $382.54. The company has a market capitalization of $8.95 billion, a PE ratio of 37.88 and a beta of 0.50. The company's 50-day simple moving average is $336.45 and its two-hundred day simple moving average is $308.70.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its quarterly earnings data on Monday, November 2nd. The company reported $2.05 EPS for the quarter, topping analysts' consensus estimates of $1.79 by $0.26. The firm had revenue of $127.34 million during the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a return on equity of 19.34% and a net margin of 54.82%. Research analysts anticipate that Krystal Biotech will post 7.33 EPS for the current fiscal year.

Insider Activity

In related news, Director Dino Rossi sold 25,000 shares of the firm's stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at approximately $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction dated Friday, September 4th. The stock was sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the sale, the insider directly owned 1,302,145 shares in the company, valued at approximately $467,886,741.40. This represents a 1.88% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.10% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Krystal Biotech

Institutional investors have recently bought and sold shares of the company. Parallel Advisors LLC increased its position in shares of Krystal Biotech by 2.0% during the 3rd quarter. Parallel Advisors LLC now owns 1,733 shares of the company's stock valued at $576,000 after purchasing an additional 34 shares during the last quarter. Signaturefd LLC raised its stake in shares of Krystal Biotech by 27.3% during the third quarter. Signaturefd LLC now owns 168 shares of the company's stock valued at $56,000 after acquiring an additional 36 shares during the last quarter. Torray Investment Partners LLC grew its position in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company's stock worth $3,108,000 after buying an additional 47 shares during the last quarter. Oregon Public Employees Retirement Fund increased its position in Krystal Biotech by 0.9% during the 1st quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company's stock valued at $1,537,000 after purchasing an additional 53 shares during the period. Finally, Hanseatic Management Services Inc. raised its stake in Krystal Biotech by 2.0% in the third quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company's stock worth $1,059,000 after buying an additional 63 shares in the last quarter. Hedge funds and other institutional investors own 86.29% of the company's stock.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter earnings of $2.05 per share, above consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also exceeded expectations. The results were supported by approximately 30% revenue growth. Krystal Biotech Q3 earnings beat
• Positive Sentiment: The company authorized a $400 million share-repurchase program over two years. Buybacks can support near-term earnings per share and signal management’s confidence in the stock’s value. Krystal $400 million buyback
• Positive Sentiment: TD Cowen and Royal Bank of Canada lowered their price targets to $380 and $375, respectively, but retained bullish ratings of Buy and Outperform. Both targets imply substantial upside from recent trading levels. TD Cowen rating Royal Bank of Canada rating
• Neutral Sentiment: The earnings beat and buyback have improved the investment case, but commentary indicates KRYS remains above some measures of fair value. Investors may therefore require continued Vyjuvek growth and pipeline progress to justify the valuation. Krystal remains above fair value
• Negative Sentiment: Third-quarter earnings declined from $2.66 per share a year earlier to $2.05, despite the consensus beat. That year-over-year deterioration likely contributed to the negative market reaction. Krystal Q3 profit decline
• Negative Sentiment: Several pipeline milestones have shifted into 2027, raising concerns about execution and delaying potential catalysts. The company also revised 2026 non-GAAP operating-expense guidance to $155 million-$165 million, highlighting ongoing investment and funding risks. Krystal pipeline timeline update

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company's platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal's lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.